Intravitreal Triamcinolone Acetonide for Treatment of Refractory Diffuse Diabetic Macular Edema
Status:
Unknown status
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
Phase I/II study with intravitreal triamcinolone acetonide microspheres(RETAAC)for treatment
of diffuse diabetic macular edema unresponsive to laser photocoagulation. Study hypothesis is
that single intravitreal injection of RETAAC is safe and efficient compared to conventional
treatment. Fifty patients will participate in this study and will be randomized into
treatment and observation groups. Efficacy will be evaluated by best corrected visual acuity
and macular thickness measured by optic coherence tomography (OCT) after 12 months of
treatment.